肝动脉化疗栓塞术联合FOLFOX方案持续性动脉灌注化疗在巴塞罗那B期原发性肝癌患者中的应用效果  

Application effect of transcatheter arterial chemoembolization combined with FOLFOX regimen continuous arterial infusion chemotherapy in patients with BCLC-B stage primary liver cancer

作　　者：柯映平[1] 叶绍光[1] 卢舜彬 KE Yingping;YE Shaoguang;LU Shunbin(Department of General Surgery,Chaozhou Central Hospital,Guangdong Province,Guangdong Province,Chaozhou 521000,China)

机构地区：[1]广东省潮州市中心医院普外科,广东潮州521000

出　　处：《中国当代医药》2022年第18期73-76,共4页China Modern Medicine

基　　金：广东省潮州市卫生健康局科研项目(潮卫科研2020068号)。

摘　　要：目的探讨肝动脉化疗栓塞术(TACE)联合FOLFOX方案持续肝动脉灌注化疗在巴塞罗那B(BCLC-B)期原发性肝癌(PHC)患者中的应用效果。方法选取2018年5月至2021年5月潮州市中心医院收治的70例BCLC-B期PHC患者为研究对象,采用随机数字表法将其分为试验组(n=35)和对照组(n=35)。试验组采用TACE+FOLFOX方案持续性肝动脉灌注化疗,对照组采用TACE治疗。比较两组的疾病控制率、客观反应率、不良反应发生率以及治疗前后肿瘤标志物水平。结果试验组客观反应率、疾病控制率高于对照组,差异有统计学意义(P<0.05)。治疗后试验组甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原(CA199)水平低于对照组,差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论TACE联合FOLFOX方案持续性肝动脉灌注化疗对BCLC-B期PHC患者近期效果良好,患者疾病控制效果明显提升,血清肿瘤标志物水平下降,安全性可耐受,值得深入研究。Objective To investigate the application effect of transcatheter arterial chemoembolization(TACE)combined with FOLFOX regimen continuous hepatic arterial infusion chemotherapy in patients with Barcelona stage B(BCLC-B)primary liver cancer(PHC).Methods Seventy patients with PHC stage BCLC-B admitted to Chaozhou Central Hospital from May 2018 to May 2021 were selected as the study subjects,and they were divided into experimental group(n=35)and control group(n=35)by random number table method.The experimental group was treated with continuous hepatic arterial infusion chemotherapy with TACE+FOLFOX regimen,and the control group was treated with TACE.The disease control rate,objective response rate,incidence of adverse reactions,and tumor marker levels before and after treatment were compared between the two groups.Results The objective response rate and disease control rate of the experimental group were higher than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA)and carbohydrate antigen(CA199)in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Continuous hepatic arterial infusion chemotherapy with TACE combined with FOLFOX regimen has a good short-term effect on patients with BCLC-B PHC.The disease control effect of patients is significantly improved,and the level of serum tumor markers is reduced.The safety is tolerable,and it is worthy of further study.

关 键 词：原发性肝癌 肝动脉栓塞 FOLFOX方案 持续性肝动脉灌注化疗 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]